MicroRNAs (miRNAs) play critical roles in various biological processes, including cell proliferation, development and host defence. However, the molecular mechanism for miRNAs in regulating bacterial-induced inflammation remains largely unclear. Here, we report that miR-301b augments pro-inflammatory response during pulmonary infection, and caffeine suppresses the effect of miR-301b and thereby augments respiratory immunity. LPS treatment or Pseudomonas aeruginosa infection induces miR-301b expression via a TLR4/MyD88/NF-κB pathway. Importantly, caffeine decreases miR-301b expression through negative regulation of the cAMP/PKA/NF-κB axis. Further, c-Myb is identified as a target of miR-301b, which positively modulates anti-inflammatory cytokines IL-4 and TGF-β1, but negatively regulates pro-inflammatory cytokines MIP-1α and IL-17A. Moreover, repression of miR-301b results in increased transcription of c-Myb and elevated levels of neutrophil infiltration, thereby alleviating infectious symptoms in mice. These findings reveal miR-301b as a new controller of inflammatory response by repressing c-Myb function to inhibit the anti-inflammatory response to bacterial infection, representing a novel mechanism for balancing inflammation.
M icroRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at post-transcriptional levels. The literature suggests that a single miRNA can play multiple roles in influencing divergent pathways by binding to different target mRNAs at 3′-untranslated regions (UTR) 1 . miRNAs have been implicated previously in many cellular processes, including but not limited to development, cellular proliferation, apoptosis and necrosis 2, 3 . More recently, findings have indicated that miRNAs may modulate immune responses at different stages, including the production of cytokines/chemokines, the expression of adhesion and co-stimulatory molecules and the release of exosomes [4] [5] [6] [7] . Several toll-like receptors (TLRs)/NF-κB-responsive miRNAs are shown to be abundantly expressed, and may be tailored to harness the TLRs/ NF-κB pathway by interfering with their target gene expression 5, 6, 8 . miRNAs may also provide feedback regulation of NF-κB signalling to maintain homeostasis 8 . Importantly, a number of miRNAs have been implicated in downregulating inflammatory responses, helping to control overzealous inflammation during host defence against pathogens and other processes both in vitro and in vivo 9, 10 .
As a metabolic stimulant, caffeine (CAF) enhances performance by reducing physical fatigue and drowsiness. CAF exerts either positive or negative effects on neurons or other cells beneficial for patients with Parkinson's disease and cancer 11, 12 . CAF has also been tested for the treatment of bronchopulmonary dysplasia in premature infants 13 . However, excessive ingestion of CAF may lead to psychiatric diseases, including mild anxiety, jitteriness and insomnia 14 . Previous studies have revealed that CAF activates the innate immune response in tumour models 15 or suppresses tumour-necrosis factor (TNF)-α via the cyclic AMP/protein kinase A (cAMP/PKA) pathway in vitro 16 . CAF could also negatively affect carcinogenesis through the regulation of DNA damage and repair 17 . More recently, CAF has been linked to regulation of miRNAs in cardiovascular diseases 18, 19 , but has not been linked to lung diseases. In particular, CAF has not been demonstrated to participate in the respiratory inflammatory response against microorganisms.
We aimed to explore the roles of CAF in host defence and in particular defined a regulatory mechanism exerted by a novel miRNA-miR-301b-in pulmonary infection. Using miScript PCR System Screening, we analysed the expression of a set of miRNAs in alveolar macrophages following CAF treatment 20 . miR-301b, miR-301a and miR-15a are significantly suppressed, and only miR-301b is determined to be responsive and plays roles in regulating inflammation during bacterial infection. We observed less neutrophil infiltration following Pseudomonas aeruginosa infection at early times in the lungs of miR-301b-mimics-transfected mice. Neutrophils are normally associated with a heightened inflammatory response and exacerbated lung injury in acute infection models [21] [22] [23] . We then dissected the molecular mechanism by which miR-301b impacts neutrophil infiltration and the inflammatory response. Our results indicate that CAF negatively regulates the inflammatory response in bacterial infection by inhibiting miR-301b and augmenting the expression of the miR-301b target c-Myb.
Results
miR-301b expression is altered by CAF both in vitro and in vivo. CAF is implicated in infection and inflammation. To search for miRNAs that may be regulated by CAF, we used MH-S cells to perform array-based miRNA profiling. Because CAF treatment at higher concentrations (>3 mM) for 24 h affected cell viability (Fig. 1a ), a safer concentration (1 mM) was used in subsequent experiments. CAF suppresses the expression of several miRNAs, among which miR-301b, 301a and 15a are the most significantly inhibited (>10-fold change) ( Fig. 1b and Supplementary Table 1 ). The expression of miR-301b, 301a and 15a in MH-S, MLE-12 and primary murine bone-marrow-derived macrophages (BMDMs) was similarly suppressed by CAF in a dose-and time-dependent manner, as determined by quantitative real-time polymerase chain reaction (qRT-PCR) ( Fig. 1c,d , Supplementary Fig. 1a ,b and Supplementary Table 2 ). The levels of miRNA expression following CAF treatment were then vigorously validated by northern blot analysis ( Fig. 1e ). To elucidate the physiological relevance of the underlying miRNA alterations, we used a mouse model to evaluate the expression of miR-301b, 301a and 15a in the lung from mice treated with CAF by qRT-PCR, which was also decreased after CAF treatment ( Fig. 1f ). These findings indicate the regulatory role of CAF in miR-301b, 301a and 15a expression in respiratory systems.
CAF inhibits miR-301b through cAMP/PKA/NF-κB signalling. miR-301b was increased during lipopolysaccharide (LPS) treatment in a time-dependent manner, while miR-301a and miR-15a were not ( Fig. 2a ). Northern blotting was performed and validated the induction of miR-301b by LPS priming (Fig. 2b ). We also determined whether TLRs play a role in miR-301b expression. LPSinduced miR-301b was markedly inhibited by depleting TLR4 in BMDMs, but was not affected by TLR2 depletion ( Fig. 2c and Supplementary Fig. 2a ). After MyD88 knockdown, LPS-induced miR-301b expression was reduced but was not affected by TIRdomain-containing adapter-inducing interferon-β (TRIF) knockdown, indicating that the induction of miR-301b is probably MyD88dependent ( Fig. 2c and Supplementary Fig. 2a ). To identify the relevant pathway that regulates miR-301b expression, we pretreated MH-S, MLE-12 and BMDM cells with a set of inflammatory regulatory inhibitors: FR180204 (ERK inhibitor), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor) and SN50 (NF-κB inhibitor) 20 .
We found that inhibition of p38 and NF-κB suppressed LPS-induced miR-301b expression ( Fig. 2d ). These findings indicate that miR-301b expression may be regulated by a TLR4/p38/NF-κB axis.
To pinpoint the mechanistic feature of this signalling axis, we used cell culture models and, surprisingly, observed that CAF inhibited LPS-induced miR-301b expression in vitro ( Fig. 2e ). Pre-incubation with CAF for 24 h led to the strongest inhibition in miR-301b in MLE-12, MH-S and BMDM cells ( Supplementary  Fig. 2b ). CAF has previously been reported to indirectly preserve cAMP by inhibiting phosphodiesterase, an enzyme that degrades cAMP, thus activating downstream PKA 24 . Next, cells were pretreated with Sp-8-Br (activator of cAMP-dependent PKA) and Rp-8-Br (PKA inhibitor), respectively 25 . Sp-8-Br was found to inhibit LPS-induced miR-301b expression ( Fig. 2f ). Phosphorylation of PKA and cAMP-response element binding protein (CREB-1) was increased upon CAF treatment, but no further increase occurred upon LPS treatment ( Supplementary Fig. 2c ). A previous report has revealed that PKA activating agents inhibit NF-κB-dependent reporter gene expression 26 . Although LPS increased the phosphorylation of p65 (p-p65), CAF decreased p-p65, as assessed by immunoblotting ( Supplementary Fig. 2c ). We found that CREB-1 was translocated into the nucleus following CAF treatment, suggesting distinct roles of CREB and NF-κB as downstream transcription factors of PKA ( Supplementary Fig. 2d ). Supplementary Fig. 2e ,f shows that p65 knockdown inhibited miR-301b expression, while knockdown of PKA or CREB-1 had no effects on miR-301b expression after LPS challenge. Additionally, PKA knockdown was found to restore the suppressed miR-301b expression after CAF treatment ( Supplementary  Fig. 2g ). Together, our data suggest that CAF regulates miR-301b expression through a cAMP signalling axis.
miR-301b modulates bacterium-induced inflammatory responses in vivo. Both mRNA and IL-4, IL-6, TNF-α and TGF-β1 protein levels were found to increase following LPS treatment, as determined by qRT-PCR and enzyme-linked immunosorbent assay (ELISA) ( Supplementary Fig. 3a ,b). To assess the regulatory mechanism in inflammation regulation, chemically synthesized mimics (301b-m) or inhibitors (301b-i) were transfected into cells. Having verified the transfection efficiencies, we studied the effects of these mimics or inhibitors on inflammatory cytokines compared to negative controls (NS-m or NS-i) ( Supplementary  Fig. 4a ). Anti-inflammatory cytokines (IL-4 and TGF-β1) induced by LPS treatment were inhibited by 301b-m but increased by 301b-i compared to negative controls, as determined by qRT-PCR or ELISA ( Supplementary Fig. 3a,b ). However, the proinflammatory cytokines (IL-6 and TNF-α) were not changed significantly by manipulating miR-301b ( Supplementary Fig. 3a,b) . Additionally, the protein levels of IL-4 and TGF-β1 in MLE-12 cells were also lower in cells overexpressing 301b-m than those in control cells, whereas 301b-i increased these anti-inflammatory cytokines, as assessed by western blotting ( Supplementary  Fig. 4b ). We next found that the conditioned medium of MLE-12 cells (treated with miR-301-m) decreased the migration capabilities of MH-S cells by ∼30% using Boyden chamber assay ( Supplementary Fig. 4c ). The viability of MH-S cells was not affected by 301b-m transfection ( Supplementary Fig. 4d ), but it did decrease their phagocytosis ability ( Supplementary Fig. 4e ,f ). Collectively, these findings suggest that miR-301b may selectively downregulate the expression of anti-inflammatory genes as well as phagocytic activities.
To determine whether the in vitro phenomenon occurs similarly in vivo and can be expanded to other bacteria, we established acute respiratory infections in cells and mice with different bacteria, P. aeruginosa (Pa), Klebsiella pneumoniae (Kp) and Streptococcus pneumoniae (Sp). These bacterial infections all induced miR-301b expression both in vitro and in vivo, but did not induce miR-15a and miR-301a ( Supplementary Fig. 5a ). To further study the physiological impact of miR-301b, systemic administration of miR-301b was performed to determine bacterium-induced gene expression in vivo. The expression of miR-301b in the lungs was consistent with in vitro data ( Supplementary Fig. 5b ). At 24 h after bacterial infection, IL-4 and TGF-β1 in bronchoalveolar lavage (BAL) were decreased by 301b-m, but IL-6 and TNF-α were not affected ( Supplementary Fig. 5c ). The lungs of mice infected with Pa were immunoblotted to detect IL-4 and TGF-β1, which produced similar results to the ELISA data ( Fig. 3a) . Interestingly, 301b-m injection resulted in higher bacterial burdens than in the NS-m group, while the effects of 301b-i were opposite those of the mimics, confirming the physiological relevance in pulmonary infection ( Fig. 3b and Supplementary  Fig. 5d ). To determine whether miR-301b contributes to inflammatory cell infiltration, we performed haematoxylin and eosin (H&E) staining and found that 301b-m overexpression markedly inhibited neutrophil recruitment upon bacterial infection ( Fig. 3c ). More severe lung injury was observed in 301b-m-treated mice, whereas less lung injury was observed in 301b-i-treated mice after Pa   a   d   0  1  2  6  12  24  0  1  2  6  12  24  0  1  2  6 Supplementary Fig. 5e ). The 301b-m was found to inhibit neutrophil recruitment following Pa infection ( Fig. 3e ). In addition, myeloperoxidase (MPO) assay demonstrated that neutrophil infiltration was decreased in 301b-m transfected mice ( Fig. 3g ). Neutrophil mobilization and recruitment to the lung is usually associated with release of chemokines/cytokines to BAL. We next performed an ELISA to detect MIP-1α and IL-17A, which showed similar reductions ( Fig. 3h ). These findings are consistent with in vitro data about phagocyte migration, suggesting that phagocyte recruitment and phagocytosis may be impacted by enhanced miR-301b levels. The inhibitory effects of miR-301b on host defence may thus be due to effects on neutrophil recruitment to the lung.
c-Myb is a target of miR-301b. c-Myb possesses a conserved miR-301b seed sequence in its 3′UTR with a high mirSVR score ( Fig. 4a ) and has been demonstrated to be a critical player in immune responses 27 . We experimentally confirmed the prediction and showed that 301b-m inhibited the activity of a luciferase reporter containing c-Myb 3′UTR, while the activity of luciferase reporters containing the mutant 3′UTR of c-Myb was not significantly altered ( Fig. 4b and Supplementary Table 3 ). Furthermore, c-Myb mRNA abundancy in BMDM from mice transfected with 301b-m was lower than that in NS-m group (Fig. 4c) . Similarly, 301b-m decreased c-Myb mRNA levels ( Fig. 4d ). Moreover, in vivo data showed that bacterial infection resulted in decreased c-Myb abundance, which was further decreased by 301b-m, but this decrease could be reversed by 301b-i ( Fig. 4e ). These data collectively identify c-Myb as a bona fide target of miR-301b.
c-Myb negatively modulates infection-induced anti-inflammatory responses.
To determine whether c-Myb plays a role in infectioninduced inflammatory responses, we knocked down c-Myb in MH-S and MLE-12 cells (Fig. 5a ). Interestingly, c-Myb mRNA decreased upon LPS stimulation, which is negatively correlated with miR-301b ( Fig. 5a ). Anti-inflammatory cytokines (IL-4 and TGF-β1) were partially reduced (∼50-60%) by c-Myb knockdown (Fig. 5a,b ). However, pro-inflammatory cytokines (IL-6 and TNF-α) did not change after c-Myb was knocked down (Fig. 5c ). Similarly, anti-inflammatory cytokines were inhibited in BAL fluids of c-Myb knockdown mice after bacterial (Pa, Kp or Sp) infection ( Supplementary Fig. 6a ). However, IL-6 or TNF-α release was not altered by c-Myb knockdown ( Supplementary  Fig. 6a ). Bacterial burdens were higher in c-Myb knockdown mice locally and systemically than in control mice ( Supplementary  Fig. 6b ). Moreover, histological analysis showed that Pa infection caused more severe tissue injury and less neutrophil infiltration in c-Myb knockdown mice ( Fig. 5d,e ). MPO assays and ELISA also showed decreased MPO activity and anti-inflammatory response in c-Myb knockdown mice, which confirmed the above observations ( Fig. 5f,g) . Overall, the results imply that c-Myb is a functional target of miR-301b in bacterial-induced inflammatory responses.
CAF decreases the susceptibility to bacterial infection in vivo. To define the direct role of CAF in bacterial invasion, we set out to elucidate how CAF administration improves cytokine production. We observed that CAF significantly decreased miR-301b levels and partially increased c-Myb mRNA levels within several hours either before or after infection ( Supplementary Fig. 7a ). Interestingly, 6 h CAF pretreatment followed by bacterial infection for 24 h led to the strongest miR-301b inhibition and highest c-Myb mRNA level in the tested times ( Supplementary Fig. 7a ). To verify whether CAF has a broad role in inflammatory responses, we used primary human alveolar macrophages to recapitulate the above results. CAF was found to prevent LPS-induced p65 nuclear translocation, but CREB-1 nuclear translocation was only changed following CAF treatment ( Supplementary Fig. 8a ). The miRNA database shows that hsa-miR-301b has two high scoring binding sites with human MYB mRNA ( Supplementary Fig. 8b ). We found that both hsa-miR-301b and hsa-miR-301a were decreased by CAF, but only hsa-miR-301b was increased by LPS stimulation ( Supplementary Fig. 8c ). Similar results were obtained in primary human alveolar macrophages, as seen in murine cells, showing that CAF increased MYB expression and enhanced LPS-induced IL-4 production ( Supplementary Fig. 8d ). Next, we focused on Pa infection to determine whether CAF has effects on inflammatory responses in a physiological context. IL-4 and TGF-β1 secretion in BAL fluids was found to be negatively correlated with miR-301b, but positively correlated with c-Myb, when mice were administrated with CAF at different times and IL-10 and TNF-α were not altered ( Supplementary Fig. 9a ). In addition, 24 h post Pa infection, the lungs (6 h pretreated with CAF group) showed similar results to the ELISA data ( Fig. 6a ). We next performed in vitro bacterial growth assays, demonstrating that CAF did not have obvious antibacterial effects (Fig. 6b ). However, CAF was able to inhibit bacterial growth in vivo, particularly with 6 h CAF pretreatment (Fig. 6c ). Furthermore, CAF significantly alleviated lung injury and increased neutrophil infiltration (Fig. 6d,e and Supplementary Fig. 10a,b) . MPO assay showed a similar increase in neutrophil MPO activity (Fig. 6f ). CAF was also found to increase MIP-1α and IL-17A levels in mouse BAL, while CAF alone has no function in the inflammatory response without infection ( Supplementary Fig. 10c,d) . We also noted no significant tissue injury in the liver and kidney ( Supplementary  Fig. 10e ). However, infection induced lower c-Myb expression in all these tissues, whereas CAF counteracted this damaging effect by increasing c-Myb expression ( Supplementary Fig. 10f ). Lower CAF treatment did not induce significant neutrophil infiltration in BAL ( Supplementary Fig. 10g ) and had limited effects on infection mitigation, as reflected by bacterial burdens ( Supplementary  Fig. 10h ). To determine a potential causal relationship, we established a gain-of-function setting using miR-301b mimics. After CAF treatment and subsequent infection, we found that CAF has no impact on levels of IL-4 and TGF-β1 in BAL (Fig. 6g) . These data suggest that CAF exerts its inflammatory regulation by impacting the levels of miR-301b. It was found that 301b-i significantly attenuated mouse mortality after Pa infection (Fig. 6h ). Systemic delivery of CAF decreased mortality following bacterial infection (Fig. 6h ). To determine whether the manipulation of CAF and miR-301b affects adaptive immunity, we stained an adaptive immunity marker (CD4 + T cell) in lung sections. CAF or miR-301b itself could not induce CD4 + T cell recruitment in lungs without infection ( Supplementary Fig. 11a ). However, Pa infection in both early and late phases increased CD4 + T cell recruitment to the lungs, which was further increased by CAF but decreased by 301b-m ( Supplementary Fig. 11b ). Furthermore, IL-2 in BAL showed similar patterns of CD4 + T cell recruitment ( Supplementary  Fig. 11c ). We also evaluated neutrophils in BAL and found that CAF played a role in the recruitment of neutrophils upon bacterial infection, which may result in stronger bacterial clearance at early times. However, miR-301b plays an opposing role in this infection process ( Supplementary Fig. 11d,e ), suggesting that neutrophils at early phases may benefit host defence, while late phases may be detrimental. Nevertheless, our data indicate that adaptive immunity, particularly the Th2 lineage, may affect later processes of infection.
The overall findings reveal a central role of CAF and miR-301b in the bacteria-induced immune response. Modulation of miR-301b may be a novel strategy to regulate the c-Myb pathway by altering inflammation to reduce lung and other organ damage, and thus may ultimately be beneficial for patients with acute infection (Fig. 6i ). We found ten other miRNAs (for example, miR-301a) with the potential to bind to the same or surrounding sites in c-Myb 3′UTR, which are very similar to miR-301b ( Supplementary  Fig. 12a ). We used miR-301a, miR-302b (ref. 20 ) and miR-15a as controls to establish the specific role of miR-301b. Although both 301a-m and 302b-m showed the potential to target c-Myb 3′UTR, only 301a-m played a similar role in LPS-induced IL-4 release in MLE-12 cells ( Supplementary Fig. 12b,c) . Overall, the results confirmed that miR-301b serves as a novel regulator of inflammatory response following bacterial infection.
Discussion
We have revealed a critical role of miR-301b in affecting inflammatory response against infection, which is negatively regulated by CAF. Using both in vitro and in vivo infection models, we show that CAF downregulates miR-301b, thereby increasing neutrophil infiltration and anti-inflammatory cytokines (IL-4 and TGF-β1). Neutrophils are normally increased with increased lung injury 22 . However, early polymorphonuclear (PMN) may be beneficial for bacterial clearance, but in late phases may not be beneficial, as excessive PMN accumulation can result in life-threatening tissue injury 21, 23 . miR-301b may inhibit the initial recruitment of neutrophils for the immune response against bacterial infection. We also found that miR-301b, by targeting c-Myb, inhibits anti-inflammatory cytokines, leading to excessive inflammation and impaired host defence. In contrast, CAF counteracts the effects of miR-301b on the inflammatory response, repressing an overzealous proinflammatory response in order to maintain homeostasis and prevent potential tissue damage and septic shock. Mechanically, CAF inhibits 3,5-cyclic nucleotide phosphodiesterase (cAMP-PDE), an enzyme that converts cAMP into non-cyclic AMP. Thus, cAMP diffuses through the cell and acts as a 'secondary messenger' to activate PKA, which in turn suppresses the activity of NF-κB. NF-κB has been reported to play fundamental roles in initiating the expression of many miRNAs, including miR-146, let-7, miR-21, miR-302b and so on [5] [6] [7] 20 . We found that increased cAMP downregulates NF-κB but does not affect TNF-α upon infection. This might be because TNF-α release is predominantly related to MAPK signalling following bacterial infection 28, 29 . This pro-inflammatory response is so strong that it is difficult to differentiate CAF effects from the drastic response to bacterial infection. We have demonstrated that the expression of miR-301b after bacterial infection is dependent on the transcriptional activity of NF-κB. Chemical inhibitors of NF-κB or siRNA interference of the NF-κB component (p65) markedly decrease infection-induced miR-301b. Previous reports have demonstrated that miR-301b promotes cell invasiveness by targeting TP63 in pancreatic carcinoma cells 30 . However, no study has linked miR-301b to the regulation of inflammatory responses against infection. Our study has therefore extended the biological significance and function of miR-301b in the control of inflammation.
Earlier work has characterized miR-155, miR-146a and 132 as critical regulators in innate immunity and autoimmune inflammation 6, 8, [31] [32] [33] [34] . We have recently identified miR-302b as a regulator of the anti-Pseudomonal inflammatory response by targeting IRAK4 (ref. 20) . Thus far, the biological function of miR-301b is largely unknown, with only a reported role in colon cancer 35, 36 . Thus, our study has dramatically extended the known function of miR-301b by adding it to the growing list of miRNAs for regulating inflammation.
The transcription factor c-Myb has been recognized as a protooncogene during cellular proliferation 37 . It has also been shown to control multiple steps of lymphocyte development and fetal hepatic haematopoiesis 4, 38 . Recently, c-Myb was reported to modulate miR-143 and play central and yet complex roles in DNA damage, DNA repair, cancer cell migration and invasion 39 . However, no study has linked c-Myb to the modulation of antiinflammatory cytokines. Anti-inflammatory cytokines are a series of immune regulatory molecules, which work to balance inflammation during severe bacterial infection, preventing excessive pro-inflammatory responses that can cause severe systemic inflammatory response syndrome (SIRS) and multiple organ damage syndrome (MODS) 40 .
Our study has demonstrated that miR-301b binds the 3′UTR of c-Myb and that c-Myb in turn regulates downstream inflammatory responses. Several anti-inflammatory cytokines, such as IL-4 and TGF-β1, were negatively regulated by miR-301b mimics upon LPS or bacterial infection both in vitro and in vivo, which requires the molecular interaction of miR-301b with c-Myb mRNA. Furthermore, CAF prevented mice from suffering severe organ injury by repressing miR-301b and thereby increasing the levels of anti-inflammatory cytokines in both LPS and infection models.
The exact mechanism of action of CAF on immune cells has been debated for some time 17 . Some studies suggest that CAF inhibits cAMP-phosphodiesterase, resulting in increased cAMP levels and activation of PKA (ref. 16 ). The cAMP-PKA signalling axis plays multiple roles in regulating complex cellular networks, including blood development, Th2 immunity and inflammation 24, 41 . Because it seems that CAF affects Th2 lineage, CAF and miR-301b manipulation may influence the adaptive immunity. Adaptive immunity needs a longer time to develop and is orchestrated by different mechanisms from the innate immunity. Nevertheless, our data suggest that Th2 lineage may affect later processes, when the adaptive immunity is activated. Indeed, CAF and miR-301b pretreatment could be seen as an earlier process of adaptive immunity, which then affects the inflammatory response. CAF may be an important regulator for both miRNAs and signalling proteins, such as c-Myb, but the underlying mechanisms are complex. In addition, CAF may possess multiple other unknown pharmacological effects and requires further investigation.
This report reveals a novel inflammatory regulator, miR-301b, which directly interacts with its target c-Myb to finely maintain a balance between two types of inflammatory factor. As mentioned above, downregulation of hyper-inflammation may be particularly beneficial for patients with severe infection and sepsis shock. In summary, we have identified a novel function of CAF in preferentially regulating the anti-inflammatory response in bacterial infection through the repression of miR-301b expression. This pathway takes effect through the regulation of c-Myb, which is targeted by miR-301b and influences NF-κB-mediated cytokine production. Downregulation of miR-301b by CAF is negatively regulated via cAMP/PKA/NF-κB signalling. Finally, augmenting c-Myb upregulates anti-inflammatory cytokine release, leading to a subdued inflammatory response. Our findings reveal miR-301b and CAF as new regulators in the inflammatory response, which may be tailored to alleviate sepsis-mediated tissue injury.
Methods
Ethics statement. Animal experiments were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of North Dakota, School of Medicine (assurance no. A3917-01). Dissections and injections were performed under anaesthesia, which was induced and maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.
Mice. TLR4 −/− and TLR2 −/− mice were provided by J. Sharma at the University of North Dakota. These mice were based on the C57BL/6J genetic background, and normal age-and sex-matched C57BL/6J mice were used as wild-type (WT) controls. Mice were kept and bred in the animal facility at the University of North Dakota 42 . Animal experiments were performed with randomization. By using 12 mice for survival assays, this gave an effective power of better than 0.9 (when α = 0.1). Other experiments used at least three mice to achieve better statistical results.
Cells. MLE-12 and MH-S cells were obtained from ATCC and cultured in HITES medium (MLE-12) and RPMI 1640 medium (MH-S) supplemented with 10% fetal bovine serum (HyClone Laboratories) and 100 U ml -1 of penicillin/streptomycin (Life Technologies) antibiotics in a 37°C incubator with 5% CO 2 . The cell lines were authenticated by phenotypic analysis and were tested for mycoplasma. Mouse alveolar macrophage cells were isolated from the lung by BAL. In brief, the trachea was cannulated with a 20-gauge catheter, and 0.9 ml BAL buffer was instilled, flushed four times and retrieved. A total of 3.0 ml bronchoalveolar lavage fluid (BALF) was retrieved from each mouse and cytospin slides prepared with 0.5 ml BALF were analysed by H&E staining (Fisher) to enumerate leukocyte subtypes based on their cellular and nuclear morphological properties. After centrifugation at 1,500 r.p.m., alveolar macrophage cells were resuspended and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. expression of other mRNAs was detected using QuantiTect SYBR Green RT-PCR Kit (Qiagen). The separate well 2-ΔΔCt cycle threshold method was used to determine relative quantities of individual miRNAs or mRNA, and these were expressed as fold changes, respectively. GAPDH was used as control throughout the manuscript.
Histological analysis. Organs were fixed in 10% formalin by a routine histological procedure 46 . BAL (5 µl) and blood were applied evenly on microscope slides. After H&E staining (Thermo Fisher), the numbers of neutrophils were counted using a light microscope. The formalin-fixed tissues were used for H&E staining or immunohistochemical staining to examine tissue damage or Ly6G expression post treatment.
Immunoblotting. Samples taken from either cells or tissues of mice after experimental treatment were lysed with RIPA buffer (30 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 10% glycerol and complete cocktail (Life technologies) and phosphatases (Sigma). Lysates were centrifuged at 14,000g for 15 min, the supernatants were collected, and concentration was quantitated. The samples were boiled for 10 min and equal amounts were applied to 12% SDSpolyacrylamide minigels and electrophoresed. The proteins in the gel were then transferred to nitrocellulose filter membranes (Thermofisher). Horseradish peroxidase (HRP)-linked secondary antibody (Rockland) and X-ray film (Kodak) were used for exposure 47, 48 . Rabbit polyclonal IgG antibody anti-GAPDH, c-Myb, MyD88, TLR4, PKA, pPKA (Thr 198), CREB-1, pCREB-1 (Ser 133), pp65 (Ser 536), TGF-β1, goat polyclonal IgG antibody anti-IL-4 and mouse monoclonal IgG antibody anti-p65 were bought from Santa Cruz Biotechnology. Rabbit polyclonal IgG antibody anti-TRIF was bought from Abcam.
Cytokine profiling and assays. Cytokine concentrations in the first 0.6 ml BAL fluid collected at the indicated times after infection were measured by standard ELISA kits following the manufacturer's instructions (eBioscience). 3-(4, 5-Dimethyl-2thiazolyl)-2, 5-diphenyltetrazolium bromide (MTT) assays were carried out following the manufacturer's instructions. Lung tissues were homogenized and equal amounts of proteins were used for MPO assays.
Confocal laser scanning microscopy. Alveolar macrophage, MH-S and MLE-12 cells were cultured in glass bottomed dishes (MatTek). Fluorescence images were obtained using an LSM 510 Meta confocal microscope (Carl Zeiss Micro Imaging) 46 . For immunostaining, the cells were fixed in 3.7% paraformaldehyde, permeabilized with 0.2% Triton X-100 in PBS and incubated with blocking buffer containing 2% BSA for 30 min. Cells were incubated with primary antibodies at 1/500 dilution in blocking buffer for 1 h and washed three times. After incubation with appropriate fluorophore-conjugated secondary antibodies, the coverslips were mounted on slides with Vectashield mounting medium. The images were captured and processed using the software provided by the manufacturer 20, 49 .
Migration assay. MLE-12 cells were transfected with NS-m or 301b-m and treated with LPS. The culture medium was collected and placed in the lower chamber. MH-S cells were loaded into the Boyden chamber with an 8 µm porous membrane (Corning) in 100 µl RPMI 1640 medium supplied with 1% serum and incubated at 37°C for 4 h. Cells were removed from the upper side of membranes, and nuclei of migratory cells on the lower side of the membrane were stained with crystal violet. MH-S cells that attached to the filter were counted by light microscopy.
Luciferase reporter assay. The sequences of the miRNAs and c-Myb used in this work can be found from the public database microRNA.org (miRanda), which revealed c-Myb as a representative target of miR-301b (higher scores indicating stronger binding). The luciferase assay report plasmid was designed by adding a sequence of c-Myb 3′UTR to the Luciferase Reporter Assay System (Promega). The designed plasmids were transfected to MLE-12 in a six-well plate for 24 h, then treated with miR-301b mimics or control mimics separately. Cell lysates were prepared for luciferase activity analysis following the manufacturer's instructions 20 .
Statistical analysis. Each experiment was conducted in triplicate or repeated at least three times. The differences in outcomes of mice are presented as percent or amount changes compared with the control after treatment. Data were analysed by one-way ANOVA (Tukey's post hoc) using Graphpad software with means ± s.d. The survival rate was calculated using a Kaplan-Meier curve from a log-rank test 50 . Differences were accepted as significant at P < 0.05.
